IBDEI0MV ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11196,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,11196,1,5,0)
 ;;=5^CML,In Remission
 ;;^UTILITY(U,$J,358.3,11196,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,11197,0)
 ;;=289.0^^64^694^55
 ;;^UTILITY(U,$J,358.3,11197,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11197,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,11197,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,11197,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,11198,0)
 ;;=238.4^^64^694^109
 ;;^UTILITY(U,$J,358.3,11198,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11198,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,11198,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,11198,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,11199,0)
 ;;=V58.61^^64^694^126
 ;;^UTILITY(U,$J,358.3,11199,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11199,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,11199,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,11199,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,11200,0)
 ;;=282.49^^64^694^117
 ;;^UTILITY(U,$J,358.3,11200,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11200,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,11200,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,11200,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,11201,0)
 ;;=289.89^^64^694^15
 ;;^UTILITY(U,$J,358.3,11201,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11201,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,11201,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,11201,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,11202,0)
 ;;=238.79^^64^694^88
 ;;^UTILITY(U,$J,358.3,11202,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11202,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,11202,1,5,0)
 ;;=5^Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,11202,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,11203,0)
 ;;=287.30^^64^694^110
 ;;^UTILITY(U,$J,358.3,11203,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11203,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,11203,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,11203,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,11204,0)
 ;;=288.09^^64^694^8
 ;;^UTILITY(U,$J,358.3,11204,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11204,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,11204,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,11204,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,11205,0)
 ;;=V10.21^^64^694^61
 ;;^UTILITY(U,$J,358.3,11205,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11205,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,11205,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,11205,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,11206,0)
 ;;=284.2^^64^694^106
 ;;^UTILITY(U,$J,358.3,11206,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11206,1,4,0)
 ;;=4^284.2
 ;;^UTILITY(U,$J,358.3,11206,1,5,0)
 ;;=5^Myelophthisic Anemia
 ;;^UTILITY(U,$J,358.3,11206,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,11207,0)
 ;;=202.40^^64^694^76
 ;;^UTILITY(U,$J,358.3,11207,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11207,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,11207,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,11207,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,11208,0)
 ;;=287.49^^64^694^118
 ;;^UTILITY(U,$J,358.3,11208,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11208,1,4,0)
 ;;=4^287.49
 ;;^UTILITY(U,$J,358.3,11208,1,5,0)
 ;;=5^Thrombocytopenia,Drug Induced
 ;;^UTILITY(U,$J,358.3,11208,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,11209,0)
 ;;=180.9^^64^694^29
 ;;^UTILITY(U,$J,358.3,11209,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11209,1,4,0)
 ;;=4^180.9
 ;;^UTILITY(U,$J,358.3,11209,1,5,0)
 ;;=5^Ca Cervix
 ;;^UTILITY(U,$J,358.3,11209,2)
 ;;=^267214
